Drug Profile
PF 4136309
Alternative Names: INCB 8761; PF-04136309; PF-4136309Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Analgesics; Antineoplastics
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatic fibrosis; Pain; Pancreatic cancer
Most Recent Events
- 10 May 2018 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in USA (PO)
- 01 May 2018 Discontinued - Phase-I for Pancreatic cancer (In volunteers) in Belgium (PO)
- 30 Jan 2018 PF 4136309 receives Orphan Drug status for Pancreatic cancer in USA before January 2018 (Pfizer pipeline, February 2018)